Aservo Equihaler is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. It is protected by 8 US drug patents filed from 2033 to 2035. All patents are active. Details of Aservo Equihaler’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
| US9913952 | 03 Sep, 2035 | Active |
| US9918995 | 18 Dec, 2033 | Active |
| US10046124 | 21 Jul, 2035 | Active |
| US10258634 | 29 Jan, 2034 | Active |
| US10441597 | 18 Dec, 2033 | Active |
| US10925964 | 28 Apr, 2034 | Active |
| US11819549 | 30 Dec, 2034 | Active |
Exclusivity Information
Aservo Equihaler holds 1 exclusivity out of which 1 has expired. Details of Aservo Equihaler's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Apr 10, 2025 |
About Aservo Equihaler
Aservo Equihaler is a drug
owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC.
Aservo Equihaler uses
Ciclesonide as the active
ingredient.
Active Ingredient:
Aservo Equihaler uses
Ciclesonide as the active ingredient.
Check out other Drugs and Companies using
Ciclesonide ingredient.